Although the potential value of these well-selected candidate genes and relevance of some of their associations were confirmed after a multivariate analysis, the majority of them had a minor impact on clinical practice, and they have not been included in the daily management of patients with chronic hepatitis C. Several pharmacogenetic/genomewide association studies (GWASs) on response to HCV treatment have identified a relationship between several polymorphisms in interferon lambda (IFN-X), transduced from the IL28B gene (19q13) region, and SVR. The gene discussed is IFNL3; the disease is chronic hepatitis C virus infection.